Using AI and Genetic Data in Drug Research to Treat a Rare Neurologic Peripheral Neuropathy with Dr. David Solomon Pharnext TRANSCRIPT
Download PDFDec 22, 2020
Dr. David Solomon, CEO, Pharnext is deploying their innovative drug discovery platform that uses genetic data, big data and AI to determine combinations that are novel and non-obvious to find treatments for rare diseases. With a focus on Charcot-Marie-Tooth, a rare neurologic peripheral neuropathy with no current...
Dec 22, 2020
Dr. David Solomon, CEO, Pharnext is deploying their innovative drug discovery platform that uses genetic data, big data and AI to determine combinations that are novel and non-obvious to find treatments for rare diseases. With a focus on Charcot-Marie-Tooth, a rare neurologic peripheral neuropathy with no current...
Acromegaly Community Educates and Improves Lives with Jill Sisco Patient Advocate TRANSCRIPT
Download PDFOct 14, 2020
Jill Sisco, President, Acromegaly Community talks about her experience with acromegaly beginning in her early twenties. She reveals how difficult it is to diagnose this condition, available therapies, and advancements in turning injectable medications into oral treatments. As a patient advocate for those who suffer from...
Oct 14, 2020
Jill Sisco, President, Acromegaly Community talks about her experience with acromegaly beginning in her early twenties. She reveals how difficult it is to diagnose this condition, available therapies, and advancements in turning injectable medications into oral treatments. As a patient advocate for those who suffer from...
Sep 17, 2020
Raj Kannan, CEO, Chiasma is focused on bringing to market oral formulations to patients that face significant challenges with their existing injectable therapies. Targeting those suffering from the rare disease acromegaly, recent approval of MYCAPSSA brings the first and only oral somatostatin analog to a predominantly...